medmix Ltd

MEDX

Equity

ISIN CH1129677105 / Valor 112967710

SIX Swiss Exchange (2024-11-21)

CHF 8.64-2.81%

medmix Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

medmix Ltd is a global market leader in high-precision delivery devices, specializing in serving the healthcare, consumer, and industrial end markets. Established as a spin-off of the Applicator Systems division of the Sulzer Group, medmix became an independent entity listed on the stock exchange in September 2021. With a strong focus on innovation and technological advancement, the company boasts over 900 active patents and operates 14 production sites worldwide. With a dedicated team of nearly 2,600 employees, medmix is committed to providing customers with uncompromising quality, proximity, and flexibility in their products and services.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Performance

In the first half of 2024, medmix Ltd reported a revenue of CHF 241.2 million, which is a 2.8% decrease compared to the same period in 2023. The decline in revenue was primarily due to a 6.1% organic revenue drop, despite a 5.4% positive impact from acquisitions. The company expects an improved performance in the second half of the year in four out of five market segments.

Profit Margins

medmix Ltd's business area gross profit for the first half of 2024 was CHF 106.2 million, representing a 2.2% decline year-on-year. However, the gross profit margin improved by 30 basis points to 44.0%. This improvement was mainly driven by the recovery in the Dental market segment revenues.

Adjusted EBITDA

The adjusted EBITDA for medmix Ltd in the first half of 2024 was CHF 46.0 million, a 7.4% decrease from the previous year. The adjusted EBITDA margin also decreased to 19.1% from 20.0% in H1 2023. This decline reflects the lower year-on-year revenues.

Free Cash Flow

medmix Ltd reported a positive free cash flow of CHF 7.6 million for the first half of 2024, a significant improvement from the negative CHF 4.9 million in the same period of 2023. This improvement was largely due to a 49.7% reduction in gross capital expenditure, which amounted to CHF 17.7 million.

Full-Year Guidance

medmix Ltd has revised its full-year 2024 guidance to reflect ongoing softness in end markets. The company now expects organic revenue growth to be flat to negative, with an adjusted EBITDA margin between 18% and 19%. This adjustment is in response to the challenging market conditions observed in the first half of the year.

Summarized from source with an LLMView Source

Key figures

-54.3%1Y

-79.8%3Y

%5Y

Performance

29.0%1Y

36.8%3Y

36.7%5Y

Volatility